Commitments and Contingencies (Details) - USD ($) |
12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Aug. 18, 2024 |
Jun. 30, 2024 |
Apr. 24, 2024 |
Jan. 17, 2024 |
Mar. 15, 2023 |
Sep. 08, 2022 |
Mar. 24, 2019 |
Apr. 01, 2018 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Commitments and Contingencies [Line Items] | ||||||||||
| License fees and milestone payments, description | More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) $275,000 upon acceptance of an NDA by the FDA and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income. | |||||||||
| Royalty expenses | $ 40,000 | $ 0 | ||||||||
| Percentage of grant funding | 5.00% | |||||||||
| Grant funding received amount | $ 1,000,000 | |||||||||
| Percentage of amount to be paid in cash | 50.00% | |||||||||
| Percentage of amount to be paid in stock | 50.00% | |||||||||
| Grant funding amount | ||||||||||
| Annual fee | $ 430,000 | $ 375,000 | ||||||||
| Recognized compensation expense | 676,200 | 796,831 | ||||||||
| Total separation agreement cost | 3,658,552 | 4,021,485 | ||||||||
| Compensation to be paid | $ 22,000 | |||||||||
| Recognized expenses | $ 36,048 | 36,050 | ||||||||
| Separation agreement description | Mr. Truluck is entitled to receive, as a consultant: (i) from November 16, 2024 through December 31, 2024, an amount equal to 100% of his most recent base salary, (ii) from January 1, 2025 through March 31, 2025, 50% of his most recent base, and (iii) from and after March 31, 2025, $350 an hour on an as needed basis. | |||||||||
| At The Market Offering Agreement [Member] | ||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||
| Recognized expenses | $ 75,000 | 298,000 | ||||||||
| Dr. Johnson’s [Member] | ||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||
| Percentage of grant funding | 10.00% | |||||||||
| Grant funding received amount | $ 1,000,000 | |||||||||
| Separation payments | $ 56,792 | |||||||||
| Payment due | $ 40,000 | |||||||||
| Stock-based compensation, common stock issued for services (in Shares) | 96 | |||||||||
| Cost per share (in Dollars per share) | $ 24.5 | |||||||||
| Total separation agreement cost | $ 2,352 | |||||||||
| License With University Of Virginia Patent Foundation [Member] | ||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||
| Royalty expenses | 40,000 | |||||||||
| Separation Agreement Related Party [Member] | ||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||
| Recognized compensation expense | $ 0 | $ 108,750 | ||||||||
| Chief Operating Officer [Member] | ||||||||||
| Commitments and Contingencies [Line Items] | ||||||||||
| Recognized compensation expense | $ 25,000 | |||||||||